BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:TaiMed Biologics readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies TaiMed Biologics's drugs run\, fr
 om ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07215468-1017@assetmemo.bio
DTSTAMP:20261121T010439Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:TMB-365 / TMB-380: Phase 2 readout est. (NCT07215468)
DESCRIPTION:TMB-365 / TMB-380\, phase 2\, HIV.\nStudy: HIV-1 Virologic Supp
 ression With TMB-365 and TMB-380 Antibodies Study\nEstimated primary compl
 etion: May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tmb-
 365-tmb-380#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07215468
URL:https://assetmemo.bio/drug/tmb-365-tmb-380#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
